The venture business has a vocabulary problem. A founder working on encrypted computation may look like a crypto company to one investor, an enterprise security company to another and an artificial-intelligence infrastructure bet to a third. A researcher decoding neural activity may belong in biotech, medical devices or AI, depending on which slide happens to be on screen. PL Capital's answer is to worry less about the label and more about the underlying technical primitive. The young investment platform, founded in 2025 and connected to the Protocol Labs network, backs difficult research at the moment it begins to look like a company.
Its public shape is compact: a crypto strategy, a neurotechnology strategy and Protocol Labs Venture Studio. The common promise is support beyond capital. Founders can draw on a network built around Protocol Labs, the organization behind IPFS, Filecoin and libp2p. Protocol Labs says that network now connects more than 600 startups, service providers, funds, accelerators and foundations. For a small venture partnership, that is the interesting asset. The check can be copied. A technical community with a decade of shared context is harder to reproduce.
Three doors, one machine
PL Capital is not one broad fund pretending that every partner can underwrite every frontier. It is a family of specialist efforts sharing an operating layer. PL Capital Crypto invests in cryptographic and decentralized primitives applied to AI, physical infrastructure, enterprise software and financial rails. PLC Neurotech concentrates on brain-computer interfaces, neuroscience-oriented AI and connectomics. The venture studio works even earlier, partnering with researchers and founders who still need to form the company around the work.
Security, privacy and coordination tools that can travel into AI, enterprise systems and financial infrastructure.
BCI, NeuroAI and connectomics, from clinical restoration to longer-horizon enhancement.
Architecture, product strategy, operations and ecosystem positioning for new technical teams.
The model solves a mundane problem hiding inside ambitious science: generalist investors often arrive after the technical risk has become legible, while researchers need help before conventional metrics exist. A lab result is not a go-to-market plan. A protocol is not a legal entity. A gifted technical founder may still need recruiting, product discipline, customer introductions and someone who recognizes which engineering compromise will damage the thesis. PL Capital places itself in that awkward interval.
“Our mandate is built around primitives, not labels.”
The customers are founders before the graph goes up
PL Capital's clearest customer is a technically exceptional founder whose work requires explanation before it requires scale. On the crypto side, that can mean teams making encrypted computation practical, giving autonomous AI agents identity and risk controls, or opening the infrastructure used to train models. On the neurotechnology side, it can mean flexible neural probes, visual prostheses, high-bandwidth interfaces or models that learn from brain activity. Studio founders may arrive with research, a prototype and an incomplete organization.
The problems differ, but the financing challenge rhymes. Development cycles are uncertain. Early customers are sophisticated and scarce. Regulation may matter before revenue. Recruiting requires specialists who can distinguish serious work from an impressive abstract. The market may not yet have a familiar budget line. That makes patient capital useful, but patience alone is not a service. PL Capital's claim is that technical judgment plus network access can reduce the avoidable friction around the science.
The other customers are the limited partners in its private investment vehicles, though PL Capital does not publish fund size, assets under management or fee terms. Regulatory filings show onshore and offshore crypto funds, with Protocol VC LLC serving as the registered adviser for the crypto strategy. That is the conventional machinery beneath an unconventional thesis: pooled private capital seeking venture returns from early ownership, organized into strategies narrow enough to develop real expertise.
A portfolio that explains the thesis
The best way to understand a venture firm is to ignore its adjectives and inspect what it funds. In February 2026, PL Capital co-led a $5 million seed round for t54 Labs with Anagram and Franklin Templeton. t54 is building identity verification, real-time risk assessment and compliance infrastructure for AI agents that transact. It sits directly at PL Capital's preferred intersection: AI changes the actor, cryptography helps establish trust, and financial rails provide the use case.
Belfort offers another clean example. The KU Leuven spinout is building hardware acceleration for fully homomorphic encryption, which allows data to be processed without first being exposed in plaintext. Its $6 million 2025 seed round included Protocol VC. The technology could matter to health care, finance and public-sector customers that want computation without surrendering sensitive data. Again, “crypto” is less a consumer category than an enabling tool.
Prime Intellect is the more visible early proof point. PL Capital says it backed founders Vincent Weisser and Johannes Hagemann from the start. In July 2026, Prime Intellect announced a $130 million Series A led by Radical Ventures, with NVIDIA Ventures, Intel Capital, Dell Technologies Capital and existing investors participating. The company reported more than 6,000 customers and over $100 million in annualized revenue, selling an open stack for compute, reinforcement learning, model evaluation, deployment and continuous improvement. One fast-rising company does not validate an entire portfolio, but it clarifies the bet: open technical rails can become a business before closed platforms absorb the market.
Neurotechnology runs on a slower clock
PLC Neurotech stretches the same method across a field with different risks. Its published portfolio includes Echo, EON, Hemispheric, Integral Neuro, Merge Labs, Netholabs, Paradromics, Precision Neuroscience, Science Corporation and Synchron. Some teams build interfaces that read or write neural signals. Others model neural activity or pursue the mapping problems required to understand brain circuitry. Clinical evidence, manufacturing, surgical workflows, patient safety and regulation join the technical underwriting.
The strategy's language is unusually long-range: restore human capability today, enhance it tomorrow and evolve it over civilization's longer arc. The first clause is the commercial anchor. Science Corporation's PRIMA retinal implant, for example, is aimed at restoring functional vision for people with severe retinal disease. The later clauses make room for tools that may begin as medicine and develop into new forms of human-computer interaction. PL Capital does not have to pretend those timelines are the same. A specialist vehicle can hold both the immediate clinical case and the speculative possibility without confusing them.
The firm sits after research becomes plausible, but before the market becomes obvious.
The studio is the practical half
Protocol Labs Venture Studio is less about selecting a finished startup and more about manufacturing the conditions in which one can exist. Its core team includes Juan Benet, who works with founders on technical architecture and ecosystem positioning; Molly Mackinlay on product strategy and operational scaling; Brad Holden, an investor who previously launched the AWS Seed program; and Charlotte Kapoor on operations and founder support.
The studio's public roster includes Allo, Akave, Arkhai, BitRobot, CoinList, Crecimiento, FernAI, Number0 and Ramo. The list ranges from capital-allocation infrastructure and decentralized data to AI and network tooling. That variety reveals the boundary of the studio: not one sector, but technical projects whose creators can use a shared recipe for incorporation, positioning, recruitment and connection to an ecosystem. For researchers, the studio can be the bridge between a paper that works and an organization that keeps working.
The market position - and the test ahead
PL Capital competes for deals with several different groups at once. Deep-tech firms such as Lux Capital, DCVC and Khosla Ventures court technically ambitious founders. Crypto-native firms understand protocols and token networks. Neurotechnology investors bring clinical and device expertise. Venture studios offer company formation. PL Capital's differentiation is the combination: specialist strategies tied to an established technical network, plus a studio capable of helping create the asset rather than merely price it.
That combination also creates the central test. A network is only an advantage when founders can use it. The firm will need to show that introductions become hires, technical conversations change road maps, research relationships shorten development cycles and portfolio companies win customers they would not have reached alone. Its public portfolio is still young, and the PL Capital brand dates only to 2025. Prime Intellect's rise is encouraging; durable evidence will require more companies crossing the distance from technical promise to repeatable demand.
Still, the architecture is coherent. Frontier research is fragmenting into specialties just as its products are colliding across markets. AI agents need identity. Private data needs encrypted compute. Neural interfaces require better models. Researchers need companies, and companies need communities fluent in the research. PL Capital is building a venture platform around those seams. It is a small firm making a large organizational bet: when the categories fail, follow the primitive, then bring the network.